

RESPIRATORY WATCH

Weeks 42-43 (October 15, 2023, to October 28, 2023)

Highlights¹

The 2023-2024 season runs from August 27, 2023, to August 24, 2024

 Activity levels Sporadic influenza activity was observed in Central and Northern Zone. Overall, COVID-19 activity has been decreasing since the peak observed in week 40. Activity continues to be lower than during the same time period in 2022. An increase in RSV cases was observed this reporting period compared to the previous reporting period. Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season
 Overall, COVID-19 activity has been decreasing since the peak observed in week 40. Activity continues to be lower than during the same time period in 2022. An increase in RSV cases was observed this reporting period compared to the previous reporting period. Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths
 continues to be lower than during the same time period in 2022. An increase in RSV cases was observed this reporting period compared to the previous reporting period. Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season. ROV: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) S ICU admissions
 An increase in RSV cases was observed this reporting period compared to the previous reporting period. Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 period. Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 Laboratory-confirmed cases Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 Influenza: There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 There were 10 new cases of Influenza A, and 1 new case of Influenza B reported during weeks 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 42-43; there have been 23 cases of Influenza A and 1 case of Influenza B reported since the start of the 2023-2024 season. COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 COVID-19: There were 595 new cases of COVID-19 reported during weeks 42-43; there have been 3007 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 laboratory confirmed cases of COVID-19 since the start of the 2023-2024 season. RSV: There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 There were 24 new cases of RSV reported during weeks 42-43; there have been 52 laboratory confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been:
 confirmed case of RSV since the start of the 2023-2024 season Severity Influenza: During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 Influenza: During the 2023-2024 season there have been:
 During the 2023-2024 season there have been: 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 3 hospitalizations (non-ICU) 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 0 ICU admissions 0 deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 O deaths COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 COVID-19: During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
 During the 2023-2024 season there have been: 148 hospitalizations (non-ICU) 5 ICU admissions
148 hospitalizations (non-ICU)5 ICU admissions
5 ICU admissions
• 12 deaths
12 00000
Outbreaks
• There were 14 new long term care facility outbreaks declared in this reporting period:
o 0 Influenza
 13 COVID-19
○ 1 RSV
Syndromic surveillance
• The percentage of emergency department visits for influenza like illness (ILI) was 0.9% during this reporting period.

¹ See Appendix for data notes.

INFLUENZA




Figure 1: Laboratory-confirmed influenza cases by week (N=24), 2023-2024 season, with comparison to previous seasons, Nova Scotia²

Table 1: Number of laboratory-confirmed influenza cases by zone, current reporting periodand cumulative 2023-2024 season, Nova Scotia


ZONE	CURRENT PERIOD			CUMULATIVE 2023-2024		
ZONE	INFLUENZA A INFLUENZA B TOTAL		INFLUENZA A	INFLUENZA B	TOTAL	
Western	0	0	0	0	0	0
Northern	7	1	8	16	1	17
Eastern	0	0	0	3	0	3
Central	3	0	3	4	0	4
Nova Scotia Total	10	1	11	23	1	24

² There were no reported influenza cases during the 2020-2021 season.

Table 2: Number of laboratory-confirmed influenza cases by age group, current reportingperiod and cumulative 2023-2024 season, Nova Scotia

	CURRENT PERIOD			CUMULATIVE 2023-2024		
AGE (YEARS)	INFLUENZA A	INFLUENZA B	TOTAL	INFLUENZA A	INFLUENZA B	TOTAL
0-4	2	0	2	2	0	2
5-19	3	0	3	3	0	3
20-44	3	0	3	6	0	6
45-64	0	0	0	7	0	7
65+	2	1	3	5	1	6
Nova Scotia Total	10	1	11	23	1	24

Figure 2. Number of influenza hospitalizations and ICU admissions by week, 2023-2024 season, Nova Scotia³




³ Due to influenza outcome reporting cycles, a data delay prevents reporting on the most recent surveillance week. If a case is hospitalized and moves to ICU in the same reporting week, they will appear in both the hospitalization and ICU columns for that week.

Table 3: Hospitalizations, ICU admissions, and deaths for influenza positive patients, based on most severe outcome, cumulative counts, 2023-2024 season, Nova Scotia⁴

	CUMULATIVE 2023-2024			
AGE (years)	Hospitalizations	ICU	Deaths	
0-4	0	0	0	
5-19	0	0	0	
20-44	0	0	0	
45-64	2	0	0	
65+	1	0	0	
Nova Scotia Total	3	0	0	

Figure 3: Cumulative influenza hospitalizations and ICU admissions, by week, 2023-24 season compared to prior seasons, Nova Scotia⁵



 ⁴ In this table, only the most severe outcome for a case is included; numbers of hospitalizations and ICU admissions could therefore decline over time, if a person counted in one of those columns moves to a more severe outcome.
 ⁵ There were no reported cases of influenza during the 2020-2021 season.

COVID-19




Figure 4: Laboratory-confirmed COVID-19 cases by week (N=3007), 2023-2024 season, with comparison to previous season, Nova Scotia


Table 4: Number of laboratory-confirmed COVID-19 cases by zone, current period and cumulative 2023-2024 season, Nova Scotia

ZONE	CURRENT PERIOD	CUMULATIVE 2023-2024
Western	165	708
Northern	127	452
Eastern	108	520
Central	195	1327
Nova Scotia Total	595	3007

Table 5. Number of laboratory-confirmed COVID-19 cases by age group, current period andcumulative 2023-2024 season, Nova Scotia

AGE (YEARS)	CURRENT PERIOD	CUMULATIVE 2023-2024
0-4	9	26
5-19	6	42
20-44	85	448
45-64	132	696
65+	363	1795
Nova Scotia Total	595	3007

Figure 5: Number of COVID-19 hospitalizations and ICU admissions by week, 2023-2024 season, Nova Scotia⁶



⁶ Due to COVID-19 outcome reporting cycles, a data delay prevents reporting on the most recent surveillance week. If a case is hospitalized and moves to ICU in the same reporting week, they will appear in both the hospitalization and ICU columns for that week. COVID-19 outcome data are currently undergoing a quality review. Once the process is complete, future reports will include updated numbers.

Table 6: Hospitalizations, ICU admissions, and deaths for COVID-19 positive patients, cumulative counts, 2023-2024 season, Nova Scotia⁷

	CUMULATIVE 2023-2024			
AGE (years)	Hospitalizations	ICU	Deaths	
0-4	0	0	0	
5-19	0	0	0	
20-44	0	0	0	
45-64	20	1	0	
65+	128	4	12	
Nova Scotia Total	148	5	12	


RSV

Table 7: Number of laboratory-confirmed RSV cases by age group, current reporting periodand cumulative 2023-2024 season, Nova Scotia

AGE (YEARS)	CURRENT PERIOD	CUMULATIVE 2023-2024
0-5 months	3	7
6-11 months	0	1
12-23 months	3	8
2-4 years	6	14
5-19 years	0	2
20-64 years	2	6
65+ years	10	14
Nova Scotia Total	24	52


⁷ In this table, only the most severe outcome for a case is included; numbers of hospitalizations and ICU admissions could therefore decline over time, if a person counted in one of those columns moves to a more severe outcome. COVID-19 outcome data are currently undergoing a quality review. Once the process is complete, future reports will include updated numbers.

Figure 6: Laboratory-confirmed RSV cases by week (N=52)⁸, 2023-2024 season, with comparison to previous seasons, Nova Scotia⁹



RESPIRATORY OUTBREAKS

Figure 7. Number of new long term care facility respiratory outbreaks by week and respiratory virus (influenza, COVID-19 and RSV), 2023-2024 season, Nova Scotia¹⁰



Surveillance week

⁸ Number was revised due to a typographical error in initial published report.

⁹ There were no reported RSV cases during the 2020-2021 season.

¹⁰ Outbreak definitions can be found in the Appendix.

SYNDROMIC SURVEILLANCE




Figure 8: Percentage of emergency department visits due to ILI by report week, 2023-2024 season, with comparison to previous seasons, Nova Scotia

OTHER RESPIRATORY ILLNESS

Table 8: Number of positive specimens for other respiratory viruses, current reporting periodand cumulative 2023-2024 season, Nova Scotia

PATHOGEN	CURRENT PERIOD	CUMULATIVE 2023-2024
Adenovirus	6	17
Bocavirus	0	0
Coronavirus*	0	0
Enterovirus/Rhinovirus	23	112
Metapneumovirus	0	1
Parainfluenza	4	19

*Excludes COVID-19

APPENDIX – DATA NOTES AND DEFINITIONS

DATA NOTES

- A surveillance week runs from Sunday to Saturday. **Nova Scotia's** 2023-2024 season is aligned with the Public Health Agency of Canada (PHAC) FluWatch surveillance weeks.
 - This year runs from August 27, 2023 (Week 35) to August 24, 2024 (Week 34).
- Notifications of hospitalizations, ICU admissions, and deaths may lag; deaths are particularly affected. Additionally, COVID-19 and influenza outcome reporting from public health occurs on Wednesdays. As a result, data are incomplete for the most recent week. Because of this, the most recent surveillance week is not included in graphs showing outcomes by week.
- The definition for a COVID-19 hospitalization was changed in May 2023.
- A case can have more than one outcome (e.g., be hospitalized, and later move to the ICU); multiple outcomes per case are counted in graphs showing outcomes by week, where applicable.
- RSV is not a notifiable disease in Nova Scotia.
- Testing eligibility guidelines and the use of multiplex respiratory virus testing affect the number of cases identified and reported.
 - Because not everyone gets tested or is eligible for testing, the numbers reported here under-represent the true burden of disease in the community.
 - The implementation of multiplex testing has likely led to increased detection of cases of other respiratory pathogens, including RSV.

DEFINITIONS USED IN RESPIRATORY SURVEILLANCE, AND USEFUL LINKS, 2023-2024

See: Nova Scotia's Respiratory Response Plan

ACRONYM LIST

- ICU Intensive care unit
- ILI Influenza-like illness
- **RSV** Respiratory syncytial virus

OUTBREAK DEFINITIONS

Lab Confirmed COVID-19 Outbreak

Two or more laboratory-confirmed resident cases, AND at least one is a facility acquired case, with all cases epidemiologically linked within the LTCF in a 10-day period

Lab Confirmed Influenza Outbreak

Two or more resident cases of ILI (influenza-like illness), where at least one is a laboratory confirmed case of influenza, within the LTCF in a 7-day period

Lab Confirmed Respiratory Syncytial Virus (RSV) Outbreak Two or more symptomatic residents where at least one is a laboratory confirmed case of RSV, epidemiologically linked within the LTCF in a 7-day period

ILI CASE DEFINITION

Acute onset of respiratory illness with fever and cough and with one or more of the following – sore throat, arthralgia, myalgia or prostration which is likely due to influenza. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.

OTHER CASE DEFINITIONS

See: Surveillance Guidelines | novascotia.ca

LINKS TO OTHER WEEKLY INFLUENZA REPORTS

Canada: <u>http://www.phac-aspc.gc.ca/fluwatch/</u>

World: <u>https://www.who.int/teams/global-influenza-programme/surveillance-and-</u>

monitoring/influenza-updates/current-influenza-update

US: <u>www.cdc.gov/flu/weekly</u>